申请人:Takeda Chemical Industries, Ltd.
公开号:EP0430300A3
公开(公告)日:1992-03-25
Novel xanthine derivatives of the formula (1):
wherein R1, which may be optionally bound through a hetero atom, is a hydrocarbon residue which may be substituted; one of R2 and R3 is a hydrocarbon residue which may be substituted, and the other is hydrogen or a hydrocarbon residue which may be substituted; R4 is hydrogen, halogen or nitro; R5 is a residue capable of forming an anion or a residue convertible into the anion; A is a direct bond or a spacer having atomic length of two or less; n is an integer of 1 or 2; and Y and Z, which may be the same or different, are an oxygen atom or a sulfur atom; and the pharmaceutically acceptable salts thereof have potent angiotensin II antagonist activity and hypotensive activity, thus being useful as therapeutic agents for treating circulatory system diseases such as hypertensive diseases, heart diseases, strokes, etc.
新型黄嘌呤衍生物的化学式(1):其中R1,可以选择通过杂原子结合,是一个可被替代的碳氢基团;R2和R3中的一个是可被替代的碳氢基团,另一个是氢或可被替代的碳氢基团;R4是氢、卤素或硝基;R5是能够形成阴离子或可转化为阴离子的残基;A是直接键或具有两个或更少原子长度的间隔物;n是1或2的整数;Y和Z,可以相同也可以不同,是氧原子或硫原子;及其药学上可接受的盐具有强效的血管紧张素II拮抗活性和降压活性,因此可用作治疗循环系统疾病如高血压疾病、心脏疾病、中风等的治疗剂。